Local Anesthesia
Conditions
Brief summary
The purpose of this study is to evaluate the effectiveness of administering Lidocaine and Epinephrine using an iontophoretic device treatment to provide local anesthesia to healthy adult volunteer subjects undergoing venipuncture.
Interventions
DEVICEIontophoretic Drug Delivery System with Lidocaine/Epinephrine
Active- 10.5% Lidocaine/0.179% Epinephrine
DEVICEIontophoretic Drug Delivery System with Epinephrine
Placebo- 0.179% Epinephrine
Sponsors
Dharma Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects may be of any race, either sex, and must be \>18 years of age * Healthy subjects as per medical screening * Subjects must have intact, healthy skin (no tattoos, surgical scars, skin infections, etc.) where the iontophoresis treatment will be performed * Subjects must be alert, oriented, mentally competent, and able to understand and comply with the requirements of the study * Subjects must have signed and dated a written informed consent * Female subjects of childbearing potential must have a negative pregnancy test result prior to the iontophoresis treatment
Exclusion criteria
* Subjects with a known allergy or sensitivity to lidocaine, epinephrine or other local anesthetics of the amide or ester type * Subjects with a know sensitivity to any components (e.g. adhesives) of the IDDSSubjects who have undergone venipuncture in the treatment area within the prior 2 weeks or longer if bruising or hematoma is apparent * Subjects who have taken an analgesic pain medication during the 24-hour period prior to the venipuncture in the posterior surface of the hand * Subjects with skin allergies or have skin diseases (e.g. psoriasis, eczema * Subjects with an open skin lesion at the treatment site * Subjects who are pregnant or breastfeeding * Subjects exposed to an investigational drug or device within the past 30 days or are involved concurrently in other treatment clinical trials * Subjects who participated in previous DTI/Transcu clinical studies related to this product * Subjects with known concurrent illness * Subjects with current known/admitted substance abuse (alcohol/drug) * Subjects with pacemakers and/or externally mounted electronic devices * Current or history of conditions that contraindicate use of iontophoretic treatment or venipuncture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Following the iontophoresis treatment an IV will be inserted into the treatment area and the amount of pain will be assessed using the median visual analog pain scale (VAS). | 4 hours |
| Monitor the nature and frequency of adverse events associated with the iontophoretic device through observation during treatment. | 4 hours |
Secondary
| Measure | Time frame |
|---|---|
| Determining the duration of anesthesia through standard pin prick testing. | 4 hours |
Countries
United States
Outcome results
None listed